- Replimune ( NASDAQ: REPL ) on Wednesday announced a proposed public offering of up to $125M of shares and pre-funded warrants.
- All securities in the offering will be offered by REPL, the company said in a statement .
- Earlier in the day, REPL announced a collaboration with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to study combination therapies for colorectal cancer and hepatocellular carcinoma.
- That news sent REPL stock surging, with the biotech earlier closing +22.2% at $23.09.
For further details see:
Replimune announces proposed public offering of up to $125M